The approval is backed by results from Lilly’s ATTAIN clinical trial program, which showed significant weight loss among participants
Eylea 2mg (intravitreal aflibercept injection) is an anti-VEGF therapy that blocks a protein responsible for abnormal blood vessel growth and leakage in the retina
The program, which has been active for over a decade, will now expand its reach, focusing on equitable access to education, resources, and community-driven solutions for patients and care partners
The open-label trial involved 105 adults with schizophrenia who were on a stable dose of an oral atypical antipsychotic for at least six weeks
The decision is based on the phase 3 DESTINY-Breast11 trial
Allergan also presented new insights on the growing population of patients on GLP-1 agonists for weight loss who are seeking aesthetic treatments
The SCOUT-HCM trial hit its primary endpoint, showing a clinically meaningful and statistically significant reduction in Valsalva left ventricular outflow tract
This strategic acquisition enables CORONA Remedies to penetrate deeper into targeted specialty and offer wider accessibility
Over the past few months, Apollo Hospitals has entered into MoUs with multiple national and international air ambulance service providers
Price of the starting dose of Ozempic and Wegovy reduced by 36% and 48% respectively
Subscribe To Our Newsletter & Stay Updated
